The American College of Cardiology (ACC) develops a number of policy documents to
provide members with guidance on clinical topics. Although clinical practice guidelines …

Despite increased awareness, poor adherence to treatments for chronic diseases remains a
global problem. Adherence issues are common in patients taking antihypertensive therapy …

W 2011 roku ESC opublikowało pierwsze wytyczne dotyczące rozpoznawania i leczenia
chorób tętnic obwodowych (PAD)[1]. Ta publikacja wypełniła ważną lukę wśród wytycznych …

Background Idarucizumab, a monoclonal antibody fragment, was developed to reverse the
anticoagulant effect of dabigatran. Methods We performed a multicenter, prospective, open …

The management of perioperative bleeding involves multiple assessments and strategies to
ensure appropriate patient care. Initially, it is important to identify those patients with an …

Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …

Background: Dose reduction of non–vitamin K antagonist oral anticoagulants (NOACs) is
indicated in patients with atrial fibrillation (AF) with renal impairment. Failure to reduce the …

Periprocedural management of anticoagulation is a common clinical conundrum that
involves a multidisciplinary team, cuts across many specialties, and varies greatly between …

Importance Non–vitamin K oral anticoagulants (NOACs) are commonly prescribed with other
medications that share metabolic pathways that may increase major bleeding risk. Objective …

Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …